Product News from the May 6th MM&M News Brief
The FDA yesterday approved GlaxoSmithKline's Requip, a treatment for restless legs syndrome, a condition that can disrupt sleep and daily activities.
Amylin announced FDA approval of Byetta for treatment of patients with Type 2 diabetes. Byetta will be available by June 1, 2006, Amylin said.
The FDA has approved GlaxoSmithKline's Boostrix, the first combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria for adolescents.